The AACR-Bayer START grant gives early career investigators the unique opportunity to gain experience not only in academic but also in industry settings. Mark Labrecque, PhD, speaks on the impact of this grant on his career and research.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) has been primarily studied in the context of autoimmune diseases. 2019 AACR-InCyte Immuno-oncology Fellow Won Jin Ho, MD, showed how PTPN22 inhibition retards tumor growth in a T-cell- and macrophage-dependent manner.
More than half of melanomas contain extra copies of the sirtuin 5 gene. Two AACR-Bayer Innovation and Discovery grant recipients and an AACR NextGen Grant recipient, along with their colleagues, demonstrated that sirtuin 5 is required for melanoma cell proliferation and survival.
The partnership of the AACR with QuadW reflects the commitment of both organizations to make a difference in the lives of sarcoma patients by supporting the next generation of cancer researchers who are focused on sarcoma research.
It has long been suggested that consumption of red meat increases the risk of colon cancer. Scientists have now demonstrated a possible mechanistic link between the two in human tumors
A team of investigators led by 2015 KureIt-AACR Grantee Dr. Eliezer Van Allen and Dr. Toni Choueiri probed the changes in the tumor and immune system in advanced renal cell carcinoma patients who received immune check point blockade (ICB).
May is Ocular/Uveal Melanoma Cancer Awareness month. The AACR- Ocular Melanoma Foundation (OMF) partnership supports the next generation of ocular melanoma cancer researchers. AACR-OMF Fellows have made progress in identifying new treatment strategies for ocular/uveal melanoma.
For a second year in a row, the Global Scholar-in-Training Award (GSITA) program will welcome early-career researchers from around the world to a virtual American Association for Cancer Research Annual Meeting. In an ordinary year, the GSITA program provides...
2018 AACR-AstraZeneca Lung Cancer Fellow Sushil Kumar demonstrated how inhibition of an epigenetic regulator, arginine methyltransferase CARM1, resulted not only in enhanced anti-tumor activity of T cells but also increased susceptibility of tumor cells to T cell-mediated killing.
The SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team set out in 2014 to develop immune-based therapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Their efforts were spurred by the underlying hypothesis that the immunosuppressive PDA milieu could be reprogrammed into an immuno-stimulatory one capable of tumor rejection, thus converting PDA into a treatable disease.